Aberdeen Group’s ANI Pharmaceuticals ANIP Stock Holding History

Aberdeen Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.5M	Buy	271,760 +65,637	+32%	+$5.27M	0.03%	410
2026 Q1	$15.9M	Sell	206,123 -34,669	-14%	-$2.71M	0.03%	484
2025 Q4	$19M	Sell	240,792 -28,886	-11%	-$2.5M	0.03%	452
2025 Q3	$24.7M	Sell	269,678 -96,255	-26%	-$7.85M	0.04%	364
2025 Q2	$23.9M	Sell	365,933 -53,166	-13%	-$3.46M	0.04%	361
2025 Q1	$28.1M	Buy	419,099 +181,134	+76%	+$10.8M	0.05%	298
2024 Q4	$13.2M	Buy	+237,965	New	+$13.7M	0.02%	457

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's ANIP Position: Q2 2026 in Review

Aberdeen Group increased its ANI Pharmaceuticals (ANIP) stake by 32% in Q2 2026, buying an estimated $5.27M and bringing the position to 271,760 shares worth $22.5M. The position accounts for 0.03% of the portfolio, ranked #410.

Aberdeen Group first reported a position in ANIP in Q4 2024 and has held it in 7 quarters since. The position peaked at $28.1M in Q1 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Aberdeen Group held 271,760 shares of ANI Pharmaceuticals worth $22.5M as of Q2 2026.
Aberdeen Group bought 65,637 ANI Pharmaceuticals shares in Q2 2026, an estimated $5.27M.
ANI Pharmaceuticals made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #410 holding.
Aberdeen Group first reported a position in ANI Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Aberdeen Group's ANI Pharmaceuticals position peaked at $28.1M in Q1 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.